Medigene AG (MDG1.DE)
EUR 1.08
(-1.64%)
EUR 1.08
(-1.64%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -14.58 Million EUR | -214.39% |
| 2022 | 13.11 Million EUR | 302.39% |
| 2021 | -6.51 Million EUR | 69.81% |
| 2020 | -21.53 Million EUR | -25.78% |
| 2019 | -17.09 Million EUR | -11.84% |
| 2018 | -19.96 Million EUR | -45.06% |
| 2017 | -10.54 Million EUR | 10.72% |
| 2016 | -7.65 Million EUR | -24.52% |
| 2015 | -9.5 Million EUR | -187.16% |
| 2014 | -3.28 Million EUR | 54.13% |
| 2013 | -7.83 Million EUR | 51.73% |
| 2012 | -12.68 Million EUR | -47.87% |
| 2011 | -10.79 Million EUR | 41.09% |
| 2010 | -17.11 Million EUR | 18.88% |
| 2009 | -21.09 Million EUR | 18.94% |
| 2008 | -26.02 Million EUR | -169.02% |
| 2007 | -29.93 Million EUR | 51.89% |
| 2006 | -6.52 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -2.96 Million EUR | 29.94% |
| 2024 Q2 | -4.09 Million EUR | -26.17% |
| 2023 Q3 | -4.17 Million EUR | -1.42% |
| 2023 FY | - EUR | -214.39% |
| 2023 Q4 | -4.23 Million EUR | -1.47% |
| 2023 Q1 | -3.35 Million EUR | -138.55% |
| 2023 Q2 | -4.11 Million EUR | -22.86% |
| 2022 Q4 | 8.69 Million EUR | 0.0% |
| 2022 Q1 | 7.7 Million EUR | 413.68% |
| 2022 Q2 | -1.77 Million EUR | -122.99% |
| 2022 Q3 | 8.69 Million EUR | 590.82% |
| 2022 FY | - EUR | 302.39% |
| 2021 FY | - EUR | 69.81% |
| 2021 Q3 | -643 Thousand EUR | 72.68% |
| 2021 Q2 | -2.35 Million EUR | -5.66% |
| 2021 Q4 | -2.45 Million EUR | -281.96% |
| 2021 Q1 | -2.22 Million EUR | 76.3% |
| 2020 Q4 | -9.39 Million EUR | -50.42% |
| 2020 FY | - EUR | -25.78% |
| 2020 Q2 | -5.8 Million EUR | -2.5% |
| 2020 Q3 | -6.24 Million EUR | -7.66% |
| 2020 Q1 | -5.66 Million EUR | -24.15% |
| 2019 Q2 | -3.84 Million EUR | 29.42% |
| 2019 Q4 | -4.56 Million EUR | 18.74% |
| 2019 FY | - EUR | -11.84% |
| 2019 Q1 | -5.44 Million EUR | 1.07% |
| 2019 Q3 | -5.61 Million EUR | -45.98% |
| 2018 FY | - EUR | -45.06% |
| 2018 Q1 | -3.2 Million EUR | -23.19% |
| 2018 Q4 | -5.5 Million EUR | -17.34% |
| 2018 Q3 | -4.69 Million EUR | -36.15% |
| 2018 Q2 | -3.44 Million EUR | -7.42% |
| 2017 Q4 | -2.6 Million EUR | 11.69% |
| 2017 Q3 | -2.95 Million EUR | 12.2% |
| 2017 Q2 | -3.36 Million EUR | -16.18% |
| 2017 Q1 | -2.89 Million EUR | 22.98% |
| 2017 FY | - EUR | 10.72% |
| 2016 Q1 | -624 Thousand EUR | 72.24% |
| 2016 FY | - EUR | -24.52% |
| 2016 Q2 | -7.52 Million EUR | -1105.77% |
| 2016 Q4 | -3.75 Million EUR | 24.76% |
| 2016 Q3 | -4.99 Million EUR | 33.67% |
| 2015 FY | - EUR | -187.16% |
| 2015 Q4 | -2.24 Million EUR | 2.3% |
| 2015 Q3 | -2.3 Million EUR | -23.91% |
| 2015 Q2 | -1.85 Million EUR | 39.55% |
| 2015 Q1 | -3.07 Million EUR | -467.03% |
| 2014 Q4 | 837 Thousand EUR | 134.46% |
| 2014 FY | - EUR | 54.13% |
| 2014 Q3 | -2.42 Million EUR | -951.52% |
| 2014 Q2 | -231 Thousand EUR | 84.38% |
| 2014 Q1 | -1.47 Million EUR | -19.18% |
| 2013 Q4 | -1.24 Million EUR | 17.27% |
| 2013 FY | - EUR | 51.73% |
| 2013 Q1 | -2.67 Million EUR | 60.85% |
| 2013 Q2 | -1.77 Million EUR | 33.67% |
| 2013 Q3 | -1.5 Million EUR | 15.59% |
| 2012 Q2 | -2.13 Million EUR | -5.07% |
| 2012 Q4 | -6.84 Million EUR | -296.7% |
| 2012 FY | - EUR | -47.87% |
| 2012 Q3 | -1.72 Million EUR | 19.17% |
| 2012 Q1 | -2.03 Million EUR | 56.91% |
| 2011 Q1 | -2.88 Million EUR | 69.71% |
| 2011 Q2 | -2.67 Million EUR | 7.55% |
| 2011 Q3 | -165 Thousand EUR | 93.82% |
| 2011 Q4 | -4.71 Million EUR | -2756.36% |
| 2011 FY | - EUR | 41.09% |
| 2010 Q4 | -9.53 Million EUR | -196.3% |
| 2010 Q2 | -747 Thousand EUR | 64.95% |
| 2010 Q3 | -3.21 Million EUR | -330.92% |
| 2010 Q1 | -2.13 Million EUR | 63.81% |
| 2010 FY | - EUR | 18.88% |
| 2009 Q2 | -6.17 Million EUR | -259.13% |
| 2009 Q4 | -5.88 Million EUR | 9.26% |
| 2009 Q3 | -6.48 Million EUR | -5.05% |
| 2009 FY | - EUR | 18.94% |
| 2009 Q1 | -1.72 Million EUR | 0.0% |
| 2008 FY | - EUR | -169.02% |
| 2007 FY | - EUR | 51.89% |
| 2006 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| BioNTech SE | 1.08 Billion EUR | 101.341% |
| CureVac N.V. | -234.09 Million EUR | 93.769% |
| Biotest Aktiengesellschaft | 179 Million EUR | 108.148% |
| Biotest Aktiengesellschaft | 179 Million EUR | 108.148% |
| BRAIN Biotech AG | -2.38 Million EUR | -511.018% |
| Formycon AG | 81.05 Million EUR | 117.994% |
| Heidelberg Pharma AG | -18.7 Million EUR | 22.032% |